MedTrace Logo

To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors

NCT01193140 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-11-21

No results posted yet for this study

Summary

To evaluate the safety and tolerability of the veliparib/TMZ combination in subjects with solid tumors.

Conditions

  • Solid Tumor Cancers

Interventions

DRUG

veliparib

Dose orally twice daily for 7 days, consecutively, every cycle

DRUG

Temozolomide

Dose orally once daily for 5 days, consecutively, every cycle

Sponsors & Collaborators

Principal Investigators

  • Bhardwaj Dessai, MD · Abbott

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01193140 on ClinicalTrials.gov